Edition:
United States

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

19.08USD
17 Aug 2018
Change (% chg)

$-0.49 (-2.50%)
Prev Close
$19.57
Open
$19.55
Day's High
$19.55
Day's Low
$18.89
Volume
78,449
Avg. Vol
122,536
52-wk High
$25.74
52-wk Low
$10.83

Latest Key Developments (Source: Significant Developments)

Intra-Cellular Therapies Announces Positive Pre-NDA Meeting With FDA For Schizophrenia Treatment
Tuesday, 13 Mar 2018 07:30am EDT 

March 13 (Reuters) - Intra-Cellular Therapies Inc ::INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE PRE-NDA MEETING WITH FDA FOR LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA.INTRA-CELLULAR THERAPIES INC - ‍FDA AGREED ON PROPOSED CONTENT AND TIMING OF A ROLLING NDA SUBMISSION​.INTRA-CELLULAR THERAPIES INC - ‍PLANS TO COMPLETE ITS NDA SUBMISSION BY MID-2018.​.INTRA-CELLULAR THERAPIES - ‍HAD POSITIVE PRE-NDA MEETING WITH FDA REGARDING LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA​.  Full Article

Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56
Thursday, 1 Mar 2018 07:00am EST 

March 1 (Reuters) - Intra-Cellular Therapies Inc ::INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.56.CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TOTALED $464.3 MILLION AT DEC 31, 2017, VERSUS $384.1 MILLION AT DEC 31, 2016.INTRA-CELLULAR THERAPIES - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE USED PRIMARILY TO ADVANCE LUMATEPERONE DEVELOPMENT PROGRAM.INTEND TO SUBMIT A NEW DRUG APPLICATION FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA BY MID-2018.PRE-NDA MEETING WITH FDA IS SCHEDULED TO BE HELD IN LATE Q1 2018 FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA.  Full Article

Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Intra-cellular Therapies Inc ::Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia.Intra-Cellular Therapies Inc - ‍food and drug administration granted fast track designation for lumateperone for treatment of Schizophrenia​.  Full Article

Intra-Cellular Therapies Q3 loss per share $0.53
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.53.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cash, cash equivalents, investment securities totaled $328.1 million at September 30, 2017, versus $384.1 million at December 31, 2016​.Expect to complete patient enrollment in our bipolar studies in 2018​.  Full Article

Intra-Cellular starts enrollment in ITI-214 clinical trial in patients with Parkinson’s disease
Tuesday, 3 Oct 2017 08:00am EDT 

Oct 3 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular therapies announces commencement of enrollment of a clinical trial evaluating ITI-214 in patients with Parkinson’s disease.  Full Article

Intra-Cellular Therapies prices 9.7 mln shares of common stock at $15.50 per share
Wednesday, 27 Sep 2017 10:25pm EDT 

Sept 27 (Reuters) - Intra-Cellular Therapies Inc - :Intra-Cellular therapies prices $150 million public offering of common stock.Announced pricing of previously announced underwritten public offering of 9,677,419 shares of stock at public offering price of $15.50/ share.  Full Article

Intra-Cellular announces proposed public offering of common stock
Tuesday, 26 Sep 2017 04:01pm EDT 

Sept 26 (Reuters) - Intra-Cellular Therapies Inc :Intra-Cellular Therapies announces proposed public offering of common stock.Announced that it has commenced an underwritten public offering of $150 million of shares of its common stock​.Final terms of offering will be disclosed in a final prospectus supplement to be filed with SEC​.  Full Article

Intra-Cellular Therapies announces positive regulatory update on schizophrenia program
Wednesday, 23 Aug 2017 08:00am EDT 

Aug 23 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies announces positive regulatory update on schizophrenia program.Intra-Cellular Therapies Inc- ‍U.S. FDA has informed company that FDA has completed its review of company's responses to requests from FDA​.Intra-Cellular Therapies-‍requests from FDA relate to information regarding some findings in nonclinical toxicology studies of lumateperone in animals.Intra-Cellular Therapies-‍FDA agrees that co presented adequate data to support position metabolic pathway in animal species is distinctive from humans​.Intra-Cellular Therapies-‍moving forward with long-term safety study of lumateperone, intends to submit NDA for treatment of schizophrenia by mid-2018​.  Full Article

Intra-Cellular Therapies reports Q2 loss per share $0.41
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Intra-cellular Therapies Inc :Intra-Cellular Therapies reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.41.Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Intra-Cellular therapies reports Q1 loss per share $0.62
Wednesday, 10 May 2017 07:30am EDT 

May 10 (Reuters) - Intra-cellular Therapies Inc : :Intra-Cellular therapies reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.62.Q1 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.research and development (research and development) expenses for Q1 of 2017 were $21.5 million, compared to $23.4 million for Q1 of 2016.Intra-Cellular Therapies- cash, cash equivalents and investment securities totaled $367.8 million at march 31, 2017, compared to $384.1 million at December 31, 2016.Qtrly revenues $95,287.  Full Article

BRIEF-Intra-Cellular Therapies Reports Q1 Loss Per Share $0.65

* INTRA-CELLULAR THERAPIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE